244 related articles for article (PubMed ID: 21324178)
1. c-MYC expression sensitizes medulloblastoma cells to radio- and chemotherapy and has no impact on response in medulloblastoma patients.
von Bueren AO; Oehler C; Shalaby T; von Hoff K; Pruschy M; Seifert B; Gerber NU; Warmuth-Metz M; Stearns D; Eberhart CG; Kortmann RD; Rutkowski S; Grotzer MA
BMC Cancer; 2011 Feb; 11():74. PubMed ID: 21324178
[TBL] [Abstract][Full Text] [Related]
2. Tropomyosin receptor kinase C (TrkC) expression in medulloblastoma: relation to the molecular subgroups and impact on treatment response.
Friedrich C; Shalaby T; Oehler C; Pruschy M; Seifert B; Picard D; Remke M; Warmuth-Metz M; Kortmann RD; Rutkowski S; Grotzer MA; von Bueren AO
Childs Nerv Syst; 2017 Sep; 33(9):1463-1471. PubMed ID: 28695340
[TBL] [Abstract][Full Text] [Related]
3. Which clinical and biological tumor markers proved predictive in the prospective multicenter trial HIT'91--implications for investigating childhood medulloblastoma.
Grotzer MA; von Hoff K; von Bueren AO; Shalaby T; Hartmann W; Warmuth-Metz M; Emser A; Kortmann RD; Kuehl J; Pietsch T; Rutkowski S
Klin Padiatr; 2007; 219(6):312-7. PubMed ID: 18050040
[TBL] [Abstract][Full Text] [Related]
4. RNA interference-mediated c-MYC inhibition prevents cell growth and decreases sensitivity to radio- and chemotherapy in childhood medulloblastoma cells.
von Bueren AO; Shalaby T; Oehler-Jänne C; Arnold L; Stearns D; Eberhart CG; Arcaro A; Pruschy M; Grotzer MA
BMC Cancer; 2009 Jan; 9():10. PubMed ID: 19134217
[TBL] [Abstract][Full Text] [Related]
5. Enhanced inhibition of clonogenic survival of human medulloblastoma cells by multimodal treatment with ionizing irradiation, epigenetic modifiers, and differentiation-inducing drugs.
Patties I; Kortmann RD; Menzel F; Glasow A
J Exp Clin Cancer Res; 2016 Jun; 35(1):94. PubMed ID: 27317342
[TBL] [Abstract][Full Text] [Related]
6. Expression of O⁶-methylguanine-DNA methyltransferase in childhood medulloblastoma.
Faoro D; von Bueren AO; Shalaby T; Sciuscio D; Hürlimann ML; Arnold L; Gerber NU; Haybaeck J; Mittelbronn M; Rutkowski S; Hegi M; Grotzer MA
J Neurooncol; 2011 May; 103(1):59-69. PubMed ID: 20820873
[TBL] [Abstract][Full Text] [Related]
7. Anti-proliferative activity of the quassinoid NBT-272 in childhood medulloblastoma cells.
von Bueren AO; Shalaby T; Rajtarova J; Stearns D; Eberhart CG; Helson L; Arcaro A; Grotzer MA
BMC Cancer; 2007 Jan; 7():19. PubMed ID: 17254356
[TBL] [Abstract][Full Text] [Related]
8. Targeting cyclin-dependent kinase 9 sensitizes medulloblastoma cells to chemotherapy.
Song H; Bhakat R; Kling MJ; Coulter DW; Chaturvedi NK; Ray S; Joshi SS
Biochem Biophys Res Commun; 2019 Dec; 520(2):250-256. PubMed ID: 31594641
[TBL] [Abstract][Full Text] [Related]
9. Detection of lower levels of SNAP25 using multiple microarray systems and its functional significance in medulloblastoma.
Huang CJ; Lee CL; Liu CY; Huang SH; Hou JW; Chen YH; Chien CC; Ho CM; Lo WC; Hung KL
Int J Mol Med; 2017 May; 39(5):1195-1205. PubMed ID: 28339008
[TBL] [Abstract][Full Text] [Related]
10. MYC messenger RNA expression predicts survival outcome in childhood primitive neuroectodermal tumor/medulloblastoma.
Grotzer MA; Hogarty MD; Janss AJ; Liu X; Zhao H; Eggert A; Sutton LN; Rorke LB; Brodeur GM; Phillips PC
Clin Cancer Res; 2001 Aug; 7(8):2425-33. PubMed ID: 11489822
[TBL] [Abstract][Full Text] [Related]
11. Preradiation chemotherapy in advanced medulloblastoma. A Pediatric Oncology Group pilot study.
Mosijczuk AD; Nigro MA; Thomas PR; Burger PC; Krischer JP; Morantz RA; Kurdunowicz B; Mulne AF; Towbin RB; Freeman AI
Cancer; 1993 Nov; 72(9):2755-62. PubMed ID: 8402500
[TBL] [Abstract][Full Text] [Related]
12. [Childhood medulloblastoma].
Yazigi-Rivard L; Masserot C; Lachenaud J; Diebold-Pressac I; Aprahamian A; Avran D; Doz F
Arch Pediatr; 2008 Dec; 15(12):1794-804. PubMed ID: 18995998
[TBL] [Abstract][Full Text] [Related]
13. Interferon-gamma mediated up-regulation of caspase-8 sensitizes medulloblastoma cells to radio- and chemotherapy.
Meister N; Shalaby T; von Bueren AO; Rivera P; Patti R; Oehler C; Pruschy M; Grotzer MA
Eur J Cancer; 2007 Aug; 43(12):1833-41. PubMed ID: 17627812
[TBL] [Abstract][Full Text] [Related]
14. c-myc overexpression causes anaplasia in medulloblastoma.
Stearns D; Chaudhry A; Abel TW; Burger PC; Dang CV; Eberhart CG
Cancer Res; 2006 Jan; 66(2):673-81. PubMed ID: 16423996
[TBL] [Abstract][Full Text] [Related]
15. Strategy to minimize radiation burden in infants and high-risk medulloblastoma using intrathecal methotrexate and high-dose chemotherapy: A prospective registry study in Japan.
Yamasaki K; Okada K; Soejima T; Sakamoto H; Hara J
Pediatr Blood Cancer; 2020 Jan; 67(1):e28012. PubMed ID: 31544362
[TBL] [Abstract][Full Text] [Related]
16. Prognostic effect of whole chromosomal aberration signatures in standard-risk, non-WNT/non-SHH medulloblastoma: a retrospective, molecular analysis of the HIT-SIOP PNET 4 trial.
Goschzik T; Schwalbe EC; Hicks D; Smith A; Zur Muehlen A; Figarella-Branger D; Doz F; Rutkowski S; Lannering B; Pietsch T; Clifford SC
Lancet Oncol; 2018 Dec; 19(12):1602-1616. PubMed ID: 30392813
[TBL] [Abstract][Full Text] [Related]
17. Progressive disease in children with medulloblastoma/PNET during preradiation chemotherapy.
Tornesello A; Mastrangelo S; Piciacchia D; Bembo V; Colosimo C; Di Rocco C; Mastrangelo R
J Neurooncol; 1999; 45(2):135-40. PubMed ID: 10778729
[TBL] [Abstract][Full Text] [Related]
18. C-MYC expression in medulloblastoma and its prognostic value.
Herms J; Neidt I; Lüscher B; Sommer A; Schürmann P; Schröder T; Bergmann M; Wilken B; Probst-Cousin S; Hernáiz-Driever P; Behnke J; Hanefeld F; Pietsch T; Kretzschmar HA
Int J Cancer; 2000 Sep; 89(5):395-402. PubMed ID: 11008200
[TBL] [Abstract][Full Text] [Related]
19. Postoperative neoadjuvant chemotherapy before radiotherapy as compared to immediate radiotherapy followed by maintenance chemotherapy in the treatment of medulloblastoma in childhood: results of the German prospective randomized trial HIT '91.
Kortmann RD; Kühl J; Timmermann B; Mittler U; Urban C; Budach V; Richter E; Willich N; Flentje M; Berthold F; Slavc I; Wolff J; Meisner C; Wiestler O; Sörensen N; Warmuth-Metz M; Bamberg M
Int J Radiat Oncol Biol Phys; 2000 Jan; 46(2):269-79. PubMed ID: 10661332
[TBL] [Abstract][Full Text] [Related]
20. OLIG2 Is a Determinant for the Relapse of MYC-Amplified Medulloblastoma.
Xu Z; Murad N; Malawsky D; Tao R; Rivero-Hinojosa S; Holdhof D; Schüller U; Zhang P; Lazarski C; Rood BR; Packer R; Gershon T; Pei Y
Clin Cancer Res; 2022 Oct; 28(19):4278-4291. PubMed ID: 35736214
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
